Results from the discovery cohort were replicated in a second independent replication cohort comprising 23 subsequent IBD patients (9 UC/14 CD; Fig. 1C, Table 2) treated with a TNF antagonist (22 infliximab, 1 adalimumab) [23]. This evidence concerns the gene TNF and inflammatory bowel disease.